IQVIA (IQV) MedTech and Consumer Health president granted 11,180 SARs

Rhea-AI Filing Summary

IQVIA Holdings Inc. reported that officer Bhavik Patel, President, MedTech and Consumer Health, received a grant of stock appreciation rights on February 9, 2026. The award covers 11,180 derivative securities tied to 11,180 shares of common stock at a conversion or exercise price of $192.67.

These stock appreciation rights were acquired as a grant or award and are held directly. The award vests in three annual installments beginning on February 9, 2027, meaning the rights become exercisable over a three-year period starting on that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Bhavik

(Last) (First) (Middle)

C/O IQVIA HOLDINGS INC.

2400 ELLIS ROAD

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IQVIA HOLDINGS INC. [ IQV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Right	$192.67	02/09/2026		A		11,180		(1)	02/09/2036	Common Stock	11,180	$0	11,180	D

Explanation of Responses:

1. This stock appreciation right vests in three annual installments beginning on February 9, 2027.

Remarks:

President, MedTech and Consumer Health

	/s/ Matthew Gilmartin, Attorney-in-Fact for Bhavik Patel	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IQV officer Bhavik Patel report on this Form 4 for IQVIA (IQV)?

Bhavik Patel reported receiving a grant of stock appreciation rights. The award covers 11,180 derivative securities tied to 11,180 shares of IQVIA common stock, with a conversion or exercise price of $192.67, and is classified as a grant or award acquisition.

When did the stock appreciation right grant to Bhavik Patel at IQVIA (IQV) occur?

The stock appreciation right grant to Bhavik Patel occurred on February 9, 2026. This transaction date is the earliest reported, and it establishes when the 11,180 stock appreciation rights tied to common stock were awarded under his direct ownership.

How many stock appreciation rights were granted to Bhavik Patel at IQVIA (IQV)?

Bhavik Patel was granted 11,180 stock appreciation rights. Each right is linked to one share of IQVIA common stock, so the grant also represents 11,180 underlying common shares, all reflected as directly owned following the reported transaction.

What is the exercise price of Bhavik Patel’s stock appreciation rights at IQVIA (IQV)?

The stock appreciation rights granted to Bhavik Patel have a conversion or exercise price of $192.67. This price is used to determine the value realized when the rights are exercised relative to IQVIA’s common stock performance over time.

What is the vesting schedule for Bhavik Patel’s IQVIA (IQV) stock appreciation rights?

The stock appreciation rights vest in three annual installments beginning on February 9, 2027. This means the 11,180 rights become exercisable in stages over three years, starting one year after the grant date, according to the disclosed vesting footnote.

What role does Bhavik Patel hold at IQVIA (IQV) in connection with this equity grant?

Bhavik Patel serves as President, MedTech and Consumer Health at IQVIA. The Form 4 identifies him as an officer rather than a director or 10% owner, and the reported transaction reflects an officer-level grant of stock appreciation rights as compensation.